ConductScience.org, home

Paper41211166

Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities.

Parola S and 1 other. Explor Target Antitumor Ther, 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities. Papers, record 41211166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41211166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities.
PubMed
Journal
Explor Target Antitumor Ther
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2025-11-12
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Parola SSarahttps://orcid.org/0000-0002-7786-0688
2Colombo IIlariahttps://orcid.org/0000-0002-0602-8667

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References133

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139273684Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data.Int J Mol Sci2024https://conductscience.org/library/papers/39273684PubMed
239817679Cancer statistics, 2025.CA Cancer J Clin2025https://conductscience.org/library/papers/39817679PubMed
326295610T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.Blood Cancer J2015https://conductscience.org/library/papers/26295610PubMed
434011961A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells.Sci Rep2021https://conductscience.org/library/papers/34011961PubMed
539735605The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy.Front Oncol2024https://conductscience.org/library/papers/39735605PubMed
631544849Design and Production of Bispecific Antibodies.Antibodies (Basel)2019https://conductscience.org/library/papers/31544849PubMed
736936577Endometrial cancer: molecular classification and future treatments.BMJ Med2022https://conductscience.org/library/papers/36936577PubMed
838252906Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.Blood2024https://conductscience.org/library/papers/38252906PubMed
933088681Recent advances of antibody drug conjugates for clinical applications.Acta Pharm Sin B2020https://conductscience.org/library/papers/33088681PubMed
1034922633Recent advances and challenges of bispecific antibodies in solid tumors.Exp Hematol Oncol2021https://conductscience.org/library/papers/34922633PubMed
1125437562Structure and cancer immunotherapy of the B7 family member B7x.Cell Rep2014https://conductscience.org/library/papers/25437562PubMed
1223851282Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions.Methods2014https://conductscience.org/library/papers/23851282PubMed
1337304291Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.Front Immunol2023https://conductscience.org/library/papers/37304291PubMed
1438339430Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know?Cancers (Basel)2024https://conductscience.org/library/papers/38339430PubMed
1528249141Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.N Engl J Med2017https://conductscience.org/library/papers/28249141PubMed
1637857711The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.Nat Med2023https://conductscience.org/library/papers/37857711PubMed
1740427532Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy.Biomolecules2025https://conductscience.org/library/papers/40427532PubMed
1819840887Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol2010https://conductscience.org/library/papers/19840887PubMed
1928916367Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017https://conductscience.org/library/papers/28916367PubMed
2028182247Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.Clin Pharmacol Ther2017https://conductscience.org/library/papers/28182247PubMed

See all 133 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42649936Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.Cancers (Basel)2026https://conductscience.org/library/papers/42649936PubMed
42494820Targeting glucocorticoid receptor signaling in platinum-resistant ovarian cancer: translational rationale and clinical advances following the ROSELLA trial.Oncol Rev2026https://conductscience.org/library/papers/42494820PubMed
41827159Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine.J Clin Med2026https://conductscience.org/library/papers/41827159PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41211166

GET https://conductscience.org/api/papers/v1/41211166/references?page=2